Stock Library / ARWR

ARWR Unclassified Latest YouTube: Q3 FY2026 Published 2026-08-05

ARWR

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Arrowhead (ARWR): A 70% Revenue Beat - And Only $2.4M Of It Was Actual Medicine

Published 2026-08-05

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q3 FY2026

2026-08-05

Podcast available

Yes

Current price

$85.83

-2.60 (-2.94%)

Trailing / Forward P/E

—

Forward: -18.65x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

171.0%

Earnings: —

Margins

-226.0% op

Gross: 100.0% · Net: -47.8%

Balance sheet

5.90x current

Debt / Equity: 296.0

52-week range / Beta

$15.01 - $95.49

Beta: 1.29

Analyst target

$108.73

Upside: 26.7%

Cash / shareholder return

-0.40% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 26.02x

Return on equity: -55.2%

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Price chart

Market context for ARWR

Competitive view

ARWR vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

ARWR latest YouTube video thumbnail

ARWR

ARWR

YouTube Podbean

Latest video

Q3 FY2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Palantir Technologies latest YouTube video thumbnail

Palantir Technologies

PLTR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

ARWR

$12.12B

ARWR

SSNC

$18.73B

SS&C Technologies Holdings Inc.

PLTR

$374.68B

Palantir Technologies

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

ARWR

—

ARWR

SSNC

22.9x

SS&C Technologies Holdings Inc.

PLTR

175.2x

Palantir Technologies

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

ARWR

-18.6x

ARWR

SSNC

10.3x

SS&C Technologies Holdings Inc.

PLTR

68.9x

Palantir Technologies

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

ARWR

171.0%

ARWR

SSNC

10.3%

SS&C Technologies Holdings Inc.

PLTR

92.8%

Palantir Technologies

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

ARWR

—

ARWR

SSNC

34.7%

SS&C Technologies Holdings Inc.

PLTR

215.4%

Palantir Technologies

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

ARWR

-226.0%

ARWR

SSNC

24.6%

SS&C Technologies Holdings Inc.

PLTR

47.1%

Palantir Technologies

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

ARWR

100.0%

ARWR

SSNC

48.1%

SS&C Technologies Holdings Inc.

PLTR

84.8%

Palantir Technologies

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

ARWR

-47.8%

ARWR

SSNC

13.2%

SS&C Technologies Holdings Inc.

PLTR

49.0%

Palantir Technologies

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

ARWR

-55.2%

ARWR

SSNC

12.6%

SS&C Technologies Holdings Inc.

PLTR

38.1%

Palantir Technologies

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

ARWR

-0.4%

ARWR

SSNC

7.0%

SS&C Technologies Holdings Inc.

PLTR

0.6%

Palantir Technologies

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

ARWR

295.98x

ARWR

SSNC

115.90x

SS&C Technologies Holdings Inc.

PLTR

2.14x

Palantir Technologies

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

ARWR

5.90x

ARWR

SSNC

1.06x

SS&C Technologies Holdings Inc.

PLTR

7.23x

Palantir Technologies

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

ARWR

1.29

ARWR

SSNC

1.09

SS&C Technologies Holdings Inc.

PLTR

1.56

Palantir Technologies

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

ARWR

—

ARWR

SSNC

1.4%

SS&C Technologies Holdings Inc.

PLTR

—

Palantir Technologies

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

ARWR

26.7%

ARWR

SSNC

15.6%

SS&C Technologies Holdings Inc.

PLTR

21.1%

Palantir Technologies

Related research

Non-quarter videos featuring ARWR

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-05

ARWR beat revenue 70% - only $2.4M of it was medicine #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for ARWR

Each row is one earnings episode with every verified platform link available.

Q3 FY2026

Episode live

2026-08-05

Published youtube podcast complete

Arrowhead (ARWR): A 70% Revenue Beat - And Only $2.4M Of It Was Actual Medicine

Quarterly earnings-analysis entry for ARWR. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music